SEC Filing · 4
CytoDyn, Inc.
CYDYOTCEQUITYCurrent
SEC Filing
Company context
CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗